Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
90.6M
-
Shares change
-
+19.3M
-
Total reported value, excl. options
-
$1.99B
-
Value change
-
+$169M
-
Put/Call ratio
-
0.63
-
Number of buys
-
91
-
Number of sells
-
-27
-
Price
-
$22.00
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q2 2021
149 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q2 2021.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 90.6M shares
of 293M outstanding shares and own 30.9% of the company stock.
Largest 10 shareholders include Capital World Investors (13.4M shares), BAKER BROS. ADVISORS LP (10.5M shares), Allianz Asset Management GmbH (9.93M shares), SB Management Ltd (9.82M shares), Capital International Investors (6.89M shares), ORBIMED ADVISORS LLC (6.22M shares), HARVARD MANAGEMENT CO INC (4.11M shares), GUARDIAN CAPITAL ADVISORS LP (3.98M shares), Founders Fund VII Management, LLC (3.77M shares), and BAILLIE GIFFORD & CO (2.73M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.